Type I LAD patients express defective β2- integrin mutants, whereas β1- and β3- integrin levels are also altered in type III LAD, affecting all integrins expressed on lymphocytes as a consequence of mutations in the FERMT3 gene, leading to defective kindlin-3 expression and integrin activation [186]. The gene discussed is FERMT3; the disease is leukocyte adhesion deficiency.